Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet , 402(10404), 529-544
As a triple agonist , it simultaneously activates three distinct receptor systems [5]: GIP (Glucose-dependent Insulinotropic Polypeptide) receptors enhance insulin secretion and may have direct effects on adipose tissue GLP-1 (Glucagon-like Peptide-1) receptors promote satiety, slow gastric emptying, and improve glucose regulation Glucagon receptors increase energy expenditure and may enhance fat oxidation This multi-receptor targeting strategy distinguishes retatrutide from single-pathway peptides and creates a complex metabolic profile that researchers are still working to fully characterize
Best Practices for Safe Administration Ensuring patient safety is paramount when working with peptides
Discuss all therapies with your doctor before taking them
Mice were intraperitoneally injected with 3% thiolglycollate medium, and mouse peritoneal macrophages (MPMs) were collected after 72 h
Allow skin to fully dry
